Morphine Sulfate/Placebo for the Treatment of PulmonAry Fibrosis Cough

Inclusion Criteria:

1. Self-reported cough (> 8 weeks), with cough VAS ≥ 30/100
2. A diagnosis of IPF within 5 years prior to the screening visit, as per applicableATS/ERS/JRS/ALAT guidelines, in line with hospital records.
3. Age 3.1. Male and female participants aged ≥ 40 - 90 years at the time of signinginformed consent
4. Sex: 4.1 Male participants: A male participant must agree to use contraception as detailedin Appendix 2 of this protocol during the study and for at least 90 days after thefollow-up visit, and refrain from donating sperm during this period 4.2 Femaleparticipants: A female participant is eligible to participate if she is not pregnant,not breastfeeding, and not a woman of childbearing potential (WOCBP)
5. Meeting all of the following criteria during the screening period: FVC ≥ 45% predictedof normal, Forced expiratory volume in 1 second (FEV1)/FVC ≥0.7, DLCO corrected for Hb ≥30% predicted of normal.
6. The extent of fibrotic changes is greater than the extent of emphysema on the mostrecent HRCT scan (investigator determined within 24 months of the study screeningvisit)
7. Written informed consent.

Exclusion criteria:

1. Treatment with immunosuppressive therapy or antibiotics within last 4 weeks. A stabledose of corticosteroids equivalent to prednisolone of 10 mg per day or less, if usedfor an indication other than pulmonary disease will be permitted
2. Current smoker
3. History of alcohol and drug(s) addiction
4. Regular use of sedative therapies
5. Acute IPF exacerbation within 6 months prior to screening and/or during the screeningperiod.
6. Concurrent use of pirfenidone or Nintedanib, unless receiving a stable dose for atleast 8 weeks prior to screening
7. Use of ACE inhibitors
8. Patients with co-existent conditions know to be associated with the development offibrotic lung disease. This includes: connective tissue disease, (plural plaques,mesothelioma), granulomatous disease including sarcoidosis. Patient with auto-immuneprofile considered diagnostic for a specific connective tissue disease will beexcluded, even in the absence of systemic symptoms. Non-specific rises in autoantibodies e.g. rheumatoid factors, anti-nuclear antibody etc. will not be used toexclude individuals from the study.
9. Significant other organ co-morbidity including hepatic or renal impairment andpulmonary hypertension (investigator determined).
10. Significant coronary artery disease (myocardial infarction within 6 months or ongoingunstable angina within 4 weeks of screening visit) or congestive cardiac failure basedon clinical examination
11. Patients as significant risk of side effects, intolerance or allergy to morphine
12. Pregnant and breastfeeding patients, or women or child-bearing potential, not using areliable contraceptive method (see Appendix 2). A urine pregnancy test will beperformed in females of child-bearing potential at the initial study visit.
13. Unable to provide informed written consent
14. Predicted life expectancy < 6 months
15. Use of long-term oxygen therapy. Use of ambulatory oxygen will be permitted.
16. Current or use of opiates within 14 days of the screening visit.